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Bariatric surgery represents a common approach 
for the control of severe morbid obesity, reducing 
caloric intake by modifying the anatomy of the 
GI tract. These surgical procedures are classified 
as either restrictive, malabsorptive or a combina-
tion of both. Restrictive approaches limit calorie 
intake by creating a small gastric reservoir with a 
narrow outlet to delay emptying. Malabsorptive 
procedures, also called intestinal bypass surgery 
(IBS), bypass varying portions of the small intes-
tine where nutrient absorption occurs [1]. The 
initial effects of profound metabolic changes are 
thought to ensue directly from the bypass of the 
small intestine’s absorptive surface. As a conse-
quence, the remaining surface adapts to such a 
change with hypertrophy of the residual func-
tional units, leading to increased villus height 
and consequently an increased rate of absorption, 
which are both hallmarks of this condition [2].
Unfortunately, bariatric surgery is burdened 
by several complications, with no clear evidence 
of one procedure being the standard of care [3]. 
In general, restrictive approaches have a lower 
mortality and a decreased rate of surgical and 
nutritional complications compared with the 
malabsorptive or combined procedures [4].
After bariatric surgery, a large spectrum of 
complications has been described (outlined in 
BOX 1). Some compliations occur early, such as 
thromboembolism, pulmonary or respiratory 
failure, hemorrhage, peritonitis and wound 
infection, and some late, such as gastrointestinal 
(GI) obstruction, marginal ulceration near the 
stomach–small intestine anastomosis, incisional 
hernias, nutritional deficiencies of micronutri-
ents and dumping syndrome, which refers to a 
complex of neurohormone-mediated symptoms 
including facial f lushing,  lightheadedness, 
palpitations, fatigue and diarrhea [2,5].
Liver disease is the most common complication 
to follow jejunoileal bypass (JIB). Obese indi-
viduals show an increased incidence of fatty liver 
disease (nonalcoholic fatty liver disease) and this 
is worsened by IBS in a third of patients. In this 
group of patients, nonalcoholic fatty liver disease 
may evolve to fibrosis and cirrhosis, culminat-
ing in death [5,6]. Besides the most common 
complications, patients under going IBS, and in 
particular JIB, may subsequently develop rheu-
matic manifestation in up to 20% of cases [2]. 
In 1979, Dicken and Seehafer reported a con-
dition named bowel bypass syndrome (BBS) 
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Bariatric surgery represents a common approach for the control of severe morbid obesity, 
reducing caloric intake by modifying the anatomy of the gastrointestinal tract. Following 
jejunoileal bypass, a large spectrum of complications has been described, with rheumatic 
manifestation present in up to 20% of cases. Although bowel bypass syndrome, also called 
blind loop syndrome, is a well-recognized complication of jejunoileal bypass, the same syndrome 
was recognized in patients who had not had intestinal bypass surgery, and the term the ‘bowel-
associated dermatosis–arthritis syndrome’ (BADAS) was coined. The pathogenesis of BADAS 
is as yet poorly understood and only few data concerning this issue have been published in 
the literature. The aim of the present paper is to review the literature and to discuss putative 
pathogenic mechanisms of BADAS, focusing on the immune system.
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characterized by recurrent episodes of fever, malaise, nonerosive 
polyarthralgia or arthritis, and the development of skin lesions. 
Moreover, Raynaud’s phenomenon, paresthesias, pericarditis, 
lower limb numbness and hepatic disease are additional mani-
festations reported by patients with BBS. Symptom onset is rather 
variable, ranging from 3 months to 5 years postoperatively, and 
this syndrome may be self-limiting or recurrent [7].
Although BBS (also known as blind loop syndrome) is a well-
recognized complication of JIB, in particular of the malabsorptive 
or combination operations, the same syndrome was recognized in 
patients who had not had IBS, and Jorizzo et al. coined the term 
the ‘bowel-associated dermatosis–arthritis 
 syndrome’ (BADAS) [8].
In fact, BBS has also been observed in 
association with the small stomach and 
Roux-en-Y jejunectomy, jejunocolic bypass 
[7], ileocolic bypass [8], ileoanal pouch 
anasto mosis [9], biliopancreatic diver-
sion [10], in patients with gastric phytobe-
zoar [11], diverticulitis with sigmoid  stenosis 
[12], appendicectomy [13], Billroth II gas-
trectomy, Crohn’s disease and ulcerative 
colitis without history of bowel surgery [8].
Although several triggers have been pos-
tulated, associated risk factors are yet to be 
identified. However, rheumatologic mani-
festations following bowel bypass surgery 
seem to be more common in females and in 
those who have undergone JIB. There is no 
correlation between the amount of weight 
loss ensuing and incidence of symptoms 
[2,6,7]. Therefore, the interaction between 
surgeon and clinician and a careful evalu-
ation of patients might define possible risk 
factors.
Pathogenesis
The pathogenesis of BADAS is still poorly 
understood and only limited data have 
been published so far. Some authors have 
raised different hypotheses about the devel-
opment of BADAS as a consequence of 
bariatric surgery. The aim of the present 
paper is to review the literature and to dis-
cuss putative pathogenic mechanisms of 
BADAS, focusing on the immune system 
(FIGURES 1 & 2).
The authors postulate that the wide clini-
cal spectrum of BADAS and other immune-
related conditions after bariatric surgery is 
the consequence of immune system activa-
tion at different levels. In particular, a con-
tinuous and abnormal stimulation of both 
the innate and adaptative immune systems, 
which begins at the GI tract, together with 
vitamin and mineral deficiencies, in  particular vitamin D, may be 
the cause of these clinical conditions.
One of the most likely hypotheses is that since IBS creates 
a blind loop of small bowel, this may be colonized by intesti-
nal bacterial flora. Stasis and bacterial overgrowth are facilitated 
by the postoperative lack of peristalsis, the great length of the 
defunctionalized loop and the diversion of digestive juices and 
food [14]. In normal subjects, jejunal bacteria are typically  aerobic 
and rarely exceed 105 organisms/ml. On the contrary, in bypassed 
jejunum, up to 106 organisms/ml have been isolated, both aer-
obes and anaerobes. Bacteroides fragilis represents the most 
Box 1. Complications of bariatric surgery.
Immune-related complications
s  Articular complications: arthralgias, nonerosive arthritis, erosive arthritis, inflammatory 
back pain and tendinitis
s Myalgias
s  Panniculitis
s  Erythema nodosum
s  Cutaneous complications: skin pustules, ecchimoses, urticaria and psoriasis
s  Necrotizing vasculitis
s  Retinal vasculitis
s  Raynaud’s phenomenon
s  Serositis: pericarditis and pleural effusion
s  Peripheral nervous system complications: paresthesias and carpal tunnel syndrome
s  BADAS
Nonimmune-related complications
s  Thromboembolism
s  Pulmonary insufficiency
s Wound infection
s  Electrolyte imbalance: hypocalcaemia, hypokalemia and hypomagnesemia
s  Anemia
s  Hypoalbuminemia
s Metabolic acidosis
s  Hypoglycemia
s  Vitamin deficiency
s  Bowel complications: anastomotic leak, stricture, obstruction, diarrhea, malabsorption, 
pseudo-obstruction, intussusception, volvulus, bypass enteritis, proctitis, 
granulomatous enteritis, megacolon, pneumatosis cystoides intestinalis, hemorrhage, 
peritonitis, incisional hernias and marginal ulceration near the stomach–small intestine 
anastomosis
s  Dumping syndrome
s  Liver disease: abnormal liver function tests, fatty infiltration, fibrosis, cirrhosis and 
granulomatous hepatitis
s  Cholelithiasis
s  Kidney complications: oxalate calculi, interstitial nephritis, glomerulonephritis and 
Bartter’s syndrome
s Metabolic bone disease
s  Encephalopathy, neuritis, burning feet syndrome, meralgia paresthesia, posterolateral 
myelopathy, myotonic syndrome, optic neuropathy, Wernicke–Korsakoff 
encephalopathy and lumbosacral plexopathy
s  Infection
s  Psychological disturbance
BADAS: Bowel-associated dermatosis–arthritis syndrome.
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common pathogen among the anaerobes, while Escherichia coli 
predominates among the aerobes [15,16].
Gut injury and gut barrier failure have been considered to be 
contributors to the development of systemic inflammation and 
distant organ injury. These conditions are secondary to loss of gut 
barrier function and the eventually ensuing translocation of bacte-
ria and endotoxins from the gut to the portal and systemic circula-
tions [17]. Several authors have proposed bacterial translocation 
as a major contributor to the development of systemic infection, 
multiple-organ dysfunction syndrome and systemic inflammatory 
Figure 1. Bacterial immune complexes originating from the blind loop reach the circulatory system, accumulate in the skin 
and synovium, and lead to small-vessel damage mediated by Ns and mononuclear cells. Disturbed expression of 
proinflammatory mediators may deeply affect N rolling and migration properties and explain N activation, exocytosis and infiltration of 
the tissue. The complement system is activated by antigen–antibody complexes and through PRRs. PRRs are capable of discriminating 
between self- and nonself-antigens based on repeating PAMPs present on pathogen surfaces. PRRs are often found embedded within 
host cell membranes, either on the cell surface, on intracellular vesicles or found in the cytoplasm. PRRs are also involved in the 
immediate response to infection mediated by the innate immune system. It is generally believed that innate response to an infection aims 
to directly resist or prevent pathogen colonization by the secretion of several antimicrobial molecules, complement activation or 
inflammatory cell recruitment; this is so-called ‘innate signaling’. If a pathogen cannot be easily eradicated through the innate immune 
response, the host may act to at least limit the severity of the infection with a strategy termed ‘tolerance’. Several mechanisms have been 
described to explain how pathogens induce activation and expansion of autoreactive T cells and trigger autoimmune responses 
(molecular mimicry, bystander activation, bacterial superantigens, epitope spreading and cryptic antigens). Molecules derived from 
pathogens or commensal microorganisms and endogenous stress-induced molecules can activate T cells. In particular, DAMPs and 
MAMPs can induce inflammatory T cells either directly by binding to PRRs on T cells or indirectly through the induction of 
proinflammatory cytokine production by innate immune cells. 
APC: Antigen-presenting cell; DAMP: Damage-associated molecular pattern; DC: Dendritic cell; GI: Gastrointestinal; IC: Immune 
complex; MAMP: Microorganism-associated molecular pattern; MØ: Macrophage; N: Neutrophil; PAMP: Pathogen-associated molecular 
pattern; PRR: Pattern recognition receptor.
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response syndrome. On this basis, the authors speculate that this 
mechanism may contribute not only to systemic inflammatory 
but also to immune-related manifestations, including BADAS, 
after malabsorptive surgical procedures. In effect, JIB has been 
considered to be a classic example of bacterial translocation [18,19]. 
In this paradigm, the gut is the major source of stimuli (bacteria 
or bacterial products), which trigger an excessive release of pro-
inflammatory factors, such as cytokines, by the host immune 
cells. Moreover, the translocating bacteria and endotoxins may 
reach the liver via the portal vein and may stimulate Kupffer’s 
cells to produce proinflammatory cytokines. If the gut becomes 
a cytokine-generating organ, in particular within gut-associated 
lymphoid tissue, the mesenteric microcirculation becomes a prim-
ing bed for circulating neutrophils and other immune cells. Some 
of the translocating bacteria are phagocytosed by immune and 
nonimmune intestinal cells, thereby contributing to an intestinal 
inflammatory response [20]. Conversely, some other translocating 
bacteria escape from the intestine and are subsequently trapped 
in the intestinal lymph nodes (LNs), where they could induce an 
inflammatory reaction. In this setting, studies in animal models 
Figure 2. The mucosal immune system can be divided into inductive sites, where antigens sampled from mucosal surfaces 
stimulate naive T and B lymphocytes, and effector sites, where the effector cells after extravasation and differentiation are 
able to exert their function, including the formation of secretory IgA antibodies. Naive B and T cells enter MALT and, after 
being primed to become memory/effector B and T cells, they migrate from MALT and LNs to peripheral blood for subsequent 
extravasation at mucosal effector sites. These leukocytes are absolutely required for host homeostasis and the dysregulation of gut 
homeostasis results in several diseases such as inflammatory bowel diseases and could also play a pivotal role in the pathogenesis of 
bowel-associated dermatitis–arthritis syndrome. In the course of bowel-associated dermatitis–arthritis syndrome, the blind loop of the 
small bowel is colonized by intestinal bacterial flora. The innate immune system tries to control this bacterial overgrowth, leading to a ILF 
B-cell hypertrophy. Unfortunately in these individuals, some conditions that cause a failure of ILF B-cell-appropriate maturation and 
responsiveness may coexist and lead to dysregulation of immune system homeostasis. A key event in humoral immunity is the 
recognition of foreign antigens leading to covalent binding of C3d. This event leads to enhancement of B-cell memory and effector 
function by inducing activation and maintenance of B-cell survival within germinal centers, retention of antigen on FDC and transport of 
immune complexes to the FDC by B cells via complement receptors. 
Ag: Antigen; APC: Antigen-presenting cell; DC: Dendritic cell; FDC: Follicular dendritic cell; GC: Germinal center; ILF: Isolated lymphoid 
follicle; LN: Lymph node; M: Microfold; MALT: Mucosa-associated lymphoid tissue; SIg: Secretory immunoglobulin.
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have shown that the mesenteric LN is the first and, frequently, 
only tissue that contains translocating bacteria, suggesting that 
the intestinal lymphatic vessels are the major route by which 
gut-derived proinflammatory or toxic  factors reach the systemic 
 circulation [21].
The GI mucosa is an important immunologic center, holding 
80% of the leukocyte population, and is absolutely required for 
host homeostasis, with an estimated 100 trillion bacteria residing 
in the intestine. The dysregulation of gut homeostasis results in 
several diseases such as inflammatory bowel diseases and could 
also play a pivotal role in the pathogenesis of BADAS.
The mucosal immune system can be divided into inductive sites, 
where antigens sampled from mucosal surfaces stimulate naive 
T and B lymphocytes (present in organized mucosa-associated 
lymphoid tissue and regional draining LNs), and effector sites, 
where after extravasation and differentiation the effector cells are 
able to exert their function, including the formation of secretory 
IgA antibodies [22,23]. The effector sites consist of distinct histo-
logical compartments, including surface epithelia, the stroma of 
exocrine glands and lamina propria of various mucosae.
A single epithelial cell layer separates enteric flora and environ-
mental antigens from the sterile host and subepithelial lymphoid 
tissue is segmentally organized in follicular-associated epithe-
lium. These lymphoid sites are represented by both Peyer’s patches 
(PPs) and isolated lymphoid follicles (ILFs). The lamina propria 
compart ment is particularly enriched in plasma cells, macrophages 
and dendritic cells. Mesenteric LNs provide a draining secondary 
lymphoid compartment for the intestinal environment. These 
compartments cooperate for the induction and  organization of 
effector phases of immunity [24].
In these compartments, leukocytes are key players to maintain 
tolerance to the enteric flora and food antigens, and a defense to 
foreign infectious agents. In particular, B lymphocytes are cru-
cial in maintaining homeostasis and immunity, mainly through 
differentiation into IgA-producing plasma cells. Moreover 
intestinal plasma cells derive from B cells initially activated in 
gut-associated lymphoid tissue [22,25].
ILFs are constituted of B cells organized into a central fol-
licle that may contain a germinal center, representing a unique 
compart ment of B lymphocytes found at the host–bacterial inter-
face of the bacteria-laden intestine. Notably, ILFs, but not PPs 
and LNs, contain only minimal numbers of T cells, dendritic 
cells and macrophages, suggesting a novel mode of B-cell activa-
tion at this site. These findings highlight the role of the mucosal 
B-cell response in controlling the commensal bacterial popula-
tion, which to a certain extent is due to B-cell receptor-mediated 
antigenic stimulus [24,26,27].
After induction, ILFs induce the maturation of IgA-producing 
cells and the resulting antibodies bind and inhibit potentially 
harmful flora. Therefore, while PPs and mesenteric LNs are also 
capable of inducing B-cell differentiation into IgA plasmablasts, 
ILFs, in normal conditions, may represent the major source of 
IgA secretion [22,24].
When flora or infectious agents compromise mechanical and 
innate barriers, the failure of the appropriate maturation and 
responsiveness of ILF B cells may lead to dysregulation of homeo-
stasis. In the same way, the failure of ILF formation may result 
in insufficient antibody responsiveness, allowing infections by 
opportunistic pathogens or enteric flora [26,27].
Recent studies on ILF B cells highlight the importance of B-cell 
subsets in mediating gut homeostasis; therefore, it is conceivable 
that these cell subsets may play a pivotal role in BADAS patho-
genesis. In the course of BADAS, the blind loop of small bowel is 
colonized by intestinal bacterial flora. The innate immune system 
tries to control this bacterial overgrowth, leading to ILF B-cell 
hypertrophy. Unfortunately, in these individuals, some conditions 
that cause a failure of appropriate ILF B cells maturation and 
responsiveness may coexist, leading to dysregulation of immune 
system homeostasis.
Further studies investigating the molecular mechanisms of 
homing, retention and activation of these B-cell subsets in the 
gut mucosa will prompt us to modulate their presence and 
activity for therapeutic purposes.
Furthermore, it is conceivable that in BADAS an abnormal 
and continuous activation of the complement system (CS), could 
lead to an aberrant activation of B cells. Indeed, the importance 
of the CS in inflammation is well established and evidence sup-
ports its role in the regulation of B lymphocytes, identifying 
a link between innate and adaptive immunity. A key event in 
humoral immunity is the recognition of foreign antigens, leading 
to covalent binding of C3d. This event enhances B-cell memory 
and effector functions by inducing B-cell survival within germi-
nal centers, retention of antigen on follicular dendritic cells and 
transport of immune complexes to the follicular dendritic cells 
by B cells via  complement receptors [24,26,27].
CS molecules are ideal candidates to coordinate both earlier 
events that occur as a consequence of the induction of innate 
immunity, and those that appear later during the adaptive 
immune reaction, representing the link between innate and 
adaptive immunity [28,29].
Because of bacterial overgrowth, bacterial antigens, especially 
peptidoglycans, act as antigenic triggers for immune complex for-
mation [30]. The pathogenic role of bacteria is also supported by the 
possible improvement of the disease following antibiotic therapy 
[6]. Wands et al. evaluated five patients who developed arthritis 
after IBS to investigate whether it was associated with circulating 
cryoproteins. Only three patients displayed cryo protein complexes 
while others displayed complexes containing IgG, IgM, IgA, com-
plement components C3, C4 and C5, and IgG antibodies against 
E. coli and Bacteroides fragilis. These observations supported the 
hypothesis that systemically absorbed  intestinal bacterial antigens 
may lead to the formation of circulating cryoprotein complexes that 
can activate both the classical and alternate complement pathways 
[31]. Therefore, activation of the alternate pathway of the CS may 
also play a role in the pathogenesis of BADAS [32]. In this setting, 
it has also been reported that six out of 17 patients who displayed 
complement abnormalities 1–9 years after IBS experienced recur-
rent arthritis. The assessment of classic and alternate complement 
pathway was carried out through the levels and the ratio of com-
plement components (C3:C4, C3:C3PA, C3PA:C4) in sera. Two 
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out of those six patients also displayed activation of the alternate 
complement pathway (C3:C3PA ratio elevated) [33].
Taking into account the abnormal clearance of bacterial prod-
ucts, such as lipopolysaccharides, which occurs in the bypassed 
bowel loop, it has been claimed that this clearance of bacterial 
products may be a contributing factor in the development of com-
plement abnormalities. In addition, it has been reported that cuta-
neous injection of Streptococcus pyogenes antigen was able to induce 
skin lesions, arthritis and other signs resembling that of BADAS 
in an animal model after IBS and in patients with BBS [34].
Indeed, bacterial immune complexes originating from the blind 
loop reach the circulation, accumulate in the skin and  synovium, 
and lead to small-vessel damage mediated by neutrophils and 
mono nuclear cell migration [31]. In particular, immuno fluorescence 
analysis revealed the deposition of immune complexes in the 
dermal–epidermal junction of the skin, renal glomerulus and 
 alveolar walls [35,36].
Moreover, histologic studies of blind loops in patients with 
BADAS demonstrated changes consistent with a nonspecific 
chronic inflammatory process [14], whereas the abnormal recruit-
ment of neutrophils in the skin and synovium may reflect a more 
specific process characterized by the release of proinflammatory 
mediators, chemoattractants such as macrophage chemo attractant 
protein 1, and inflammatory chemokines such as IL-1, IL-8 and 
TNF [37]. Disturbed expression of these proinflammatory media-
tors may deeply affect neutrophil rolling and migration properties 
and explain neutrophil exocytosis and infiltration of the skin. 
Therefore, it is reasonable that these molecules cause activation 
of neutrophils with an upregulation of the expression of adhe-
sion proteins of dermis endothelial cells favoring an abnormal 
diapedesis with skin infiltration [14,32].
According to previous studies, the authors hypothesize that CS 
plays a central role in the pathogenesis of BADAS. CS is activated 
by antigen–antibody complexes and through pattern recognition 
receptors (PRRs). PRRs are able to discriminate between self- 
and nonself-antigens based on repeating patterns of molecular 
structure (pathogen-associated molecular patterns) present on 
the surface of pathogens. Complement-activating PRRs include 
mannose-binding lectin, ficolins, C-reactive protein, C1q and 
natural IgM. PRRs are often found embedded within host cell 
membranes, either on the cell surface or on intracellular vesicles 
or found in the cytoplasm. The contribution of PRRs to comple-
ment activation ensures the rapid triggering of the complement 
cascade within the early immune and inflammation response, and 
it occurs immediately, with high efficiency [28].
PRRs are also involved in the immediate response to infection 
mediated by the innate immune system. It is generally believed 
that the innate response to an infection aims to directly ‘resist’ 
or prevent pathogen colonization by the secretion of several anti-
microbial molecules, complement activation or inflammatory cell 
recruitment; this is the so-called ‘innate signaling’.
In this setting, growing evidence suggests that if a pathogen 
cannot be easily eradicated through the innate immune response, 
the host may act at least to limit the severity of the infection with 
a strategy termed ‘tolerance’ [38]; in this context, the use of this 
term reflects an attempt by the host to survive the infection and 
limit tissue damage. Such mechanisms particularly occur in the 
GI tract [39].
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) rep-
resent two families of PRRs that mediate innate responses to GI 
bacterial pathogens. In particular, NLRP1 and NLRP3 have a role 
in the aggregation and function of inflammasomes, the activation 
of caspase-1 and the subsequent cleavage of pro-IL-1b and  pro-IL-18 
to their active forms [39].
Host resistance in response to enteric bacterial infections is a 
complex process that requires several steps. First of all, commensal 
bacteria and the mucus layer provide protective barriers against 
GI bacterial pathogens. After recognition of bacterial products 
by TLRs, complex intracellular pathways are activated, leading 
to the release of antimicrobial peptides, reactive oxygen species 
and nitric oxide by intestinal epithelial cells. Intestinal epithelial 
cells, via PRR activation, release chemokines that recruit neutro-
phils, macrophages and dendritic cells to the site of infection. 
TLR2 signaling along with IL-1b and IL-18 may promote cell 
restitution/regeneration to replace injured epithelial cells; more-
over, IL-11 production by subepithelial myofibroblasts, via TLR2 
activation, promotes epithelial tight junction integrity [40]. The 
host has developed several strategies to control the potentially 
negative impact of inflammation and resistance mechanisms to 
enteric infections. On this basis, tolerance may act in order to 
limit tissue damage resulting from host resistance to infections 
of the GI tract. Other strategies include spatial regulation of 
PRR expression, control of coreceptor expression and negative 
regulation to limit responsiveness to microbes [40,41].
Taking this evidence together, it is reasonable to hypothesize 
that in the blind loop of small bowel colonized by intestinal bac-
terial flora there are alterations of these mechanisms of resistance 
and tolerance, and consequently of the innate immune response. 
Further studies to identify the peculiar role of innate immunity 
during enteric infections will surely facilitate the understanding 
of BADAS pathogenesis.
Molecules derived from pathogens or commensal micro-
organisms and endogenous stress-induced self-molecules activate 
T cells. In particular, damage-associated molecular patterns and 
microorganism-associated molecular patterns can induce inflam-
matory T cells either directly by binding to PRRs on T cells, or 
indirectly through the induction of proinflammatory cytokine 
production by innate immune cells [40,41].
This mechanism was widely described concerning both the asso-
ciation between infection and autoimmune diseases (e.g., multiple 
sclerosis, systemic lupus erythematosus and rheumatoid arthritis), 
which develop following the activation of autoreactive B and T cells, 
and between infection and chronic inflammatory diseases (such as 
Crohn’s disease), which result from uncontrolled innate and adap-
tive immune responses to normal constituents of the gut flora [37,39].
Several mechanisms have been described to explain how patho-
gens induce activation and expansion of autoreactive T cells and 
trigger autoimmune responses. Molecular mimicry has been 
linked to the pathogenesis of several rheumatic diseases [42], and 
hence may also be involved in the pathogenesis of BADAS. Such a 
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mechanism is based on the hypothesis that an exogenous substance 
may mimic self-antigens by triggering an abnormal autoimmune 
response. Interestingly, among several environmental factors, 
infectious agents have been implicated in the induction and/or 
promotion of autoimmunity, due to their capacity to elicit strong 
immune activation [42,43]. However, after activation in response 
to these pathogens, T cells may also become crossreactive to self-
antigens, eventually leading to abnormal autoimmune responses. 
Similarly, circulating antibodies were found to recognize both 
microbial and self-antigens, suggesting a crossreactivity of B-cell 
receptors [44].
T cells with a low affinity for a self-antigen, and which have 
escaped thymus negative selection, can become activated with a 
microorganism containing an identical antigen, which provides 
appropriate innate immune signals, resulting in autoimmune dis-
ease. According to the observation that specific T cells that have 
been primed by pathogens and crossreact with self-antigens can 
cause autoimmunity in animal models, the self-reactive lympho-
cytes observed at high levels in patients with autoimmune diseases 
such as systemic lupus erythematosus, rheumatoid arthritis and 
multiple sclerosis may be those triggered by microorganisms [44–46].
Another mechanism, called bystander activation, describes an 
indirect nonspecific activation of autoimmune cells caused by 
the inflammatory environment present during infection. In par-
ticular, the inflammatory setting and the paracrine secretion of 
T-cell growth factors are able to induce the expansion of activated 
autoreactive T cells [47,48].
Antigen-presenting cells, activated within the inflammatory 
milieu of a pathogenic infection, can stimulate the activation and 
proliferation of autoreactive B or T cells; antigen-presenting cells 
present self-antigens obtained following tissue destruction and/or 
uptake of local dying cells to autoreactive cells [47,48].
Notably, viral and bacterial superantigens that bind a variety of 
MHC class II molecules can activate T cells, independent of their 
specificity. In addition, activation of autoreactive B or T cells may 
be also achieved by another mechanism called ‘epitope spreading’. 
Epitope spreading is a condition in which an immune response, 
which is initiated by various stimuli, including microbial infec-
tion, trauma, transplanted tissue or autoimmunity, spreads to 
include responses directed against a different portion of the same 
protein (intramolecular spreading) or a different protein (intermo-
lecular spreading) [49]. Notably, autoimmune diseases potentially 
arise when spreading crossreacts with self-proteins, leading to the 
destruction of self-tissue [40,41].
It is generally accepted that different peptide/MHC complexes 
can lead to cross reactivity by the same T-cell receptor (TCR); this 
flexibility of TCR recognition is crucial to many immunological pro-
cesses including thymic selection and the ability to recognize nearly 
all pathogen-derived peptides. At the same time, the activation of 
TCRs by microbial antigens might lead to autoimmunity [50].
Finally, infections might also lead to autoimmunity through the 
processing and presentation of cryptic antigens. Cryptic antigens are 
normally invisible to the immune system, in contrast to dominant 
antigenic determinants. According to this theory, susceptible indi-
viduals acquire an infection by a microbial agent that has antigenic 
similarity to self-antigens resulting in pathogen-specific antibody 
binding to the host structures displaying crossreactive self-antigens 
and eventually leading to tissue damage and disease [51,52].
It can be postulated that bacterial overgrowth in the blind loop 
after IBS might favor activation of the immune system through 
molecular mimicry and other related mechanisms contributing 
to BADAS pathogenesis.
Another intriguing mechanism investigated as a potential 
environ mental trigger for the induction of autoimmunity is 
vitamin D deficiency. Bariatric surgery may also cause long-term 
morbidity due to vitamin and mineral deficiencies. Morbidly 
obese patients often display vitamin D deficiency prior to surgery 
because of poor sunlight exposure, less bioavailability of the vita-
min when sequestered in fat cells and inhibited hepatic vitamin 
activation. Bariatric surgery may then worsen vitamin D and 
calcium deficiencies due to malabsorption, reduced food intake 
and poor compliance to treatment [53].
Indeed, a high dose of vitamin D supplementation could be pre-
ventive and therapeutic, as shown in experimental auto immune 
diseases such as autoimmune encephalomyelitis, collagen-induced 
arthritis, Type 1 diabetes mellitus, inflammatory bowel disease, 
autoimmune thyroiditis and systemic lupus erythematosus [54,55]. 
Vitamin D and its active hormonal metabolite, 1,25(OH)2D3, 
are able to regulate innate and adaptive immunity; in particular, 
it potentiates the innate response (monocytes/macrophages with 
antimicrobial activity and antigen presentation) but suppresses 
adaptive immunity (T- and B-lymphocyte functions) [56].
Several immune cells including monocytes, macrophages, den-
dritic cells and activated T and B cells express vitamin D receptors and 
are provided with the enzymatic pool to convert vitamin D into its 
active form. Concerning the adaptive immune response, vitamin D 
downregulates Th1-dependent responses and directly reduces the 
production of the Th17 cytokines IL-17A, IL-17F and IL-22 by 
memory T cells [57]. It has been demonstrated that vitamin D is 
able to reduce lymphocyte proliferation, Ig production, induce 
apoptosis of activated B cells, induce regulatory B-cell development 
and inhibit the generation of plasma cells in vitro [56]. Moreover, it 
is widely accepted that vitamin D affects monocyte/macrophage 
responses to bacterial infections via TLRs [54–57].
Taken together, all the evidence allows us to speculate that 
vitamin D deficiency might also contribute to BADAS pathogen-
esis. In conclusion, our current knowledge of BADAS pathogen-
esis is too poor to be conclusive. Moreover, according to previous 
observations, the clinical spectrum of BADAS is protean and, 
after bariatric surgery, immune-related conditions other than 
BADAS have been described. On this basis, the authors are not 
able to identify a single pathogenetic mechanism described above 
in this paragraph as the most probable or the most important 
mechanism in the development of the disease.
Nonetheless, all these pathways may cooperate at different lev-
els, with different modalities and intensities. Moreover, the wide 
clinical spectrum of BADAS and other immune-related conditions 
after bariatric surgery is complex. Further studies aiming to shed 
light on BADAS pathogenesis and eventually to develop selective 
therapeutic approaches are needed.
Jejunoileal bypass: the model of BADAS
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Clinical patterns
Skin
IBS has been performed since 1956 but the first report of skin lesion 
development after IBS was described in 1981 [58]. Lesions were 
described as erythematous papules or vesiculopustules resembling 
insect bites, or as necrotic lesions similar to those seen in gonococ-
cemia. At the beginning, lesions appear as round erythematous 
macules with a 2–10-mm diameter preferentially located on the 
upper trunk and extremities, which progress toward indurated pink 
swellings usually less than 1 cm in diameter. Later the induration 
increases and develops a small vesicle with a 2–4-mm diameter and 
eventually evolves to a pustule [59]. Overall lesion duration ranged 
from 2 to 8 days with recurrence approximately every 1–6 weeks. 
BADAS belongs to noninfectious neutrophilic dermatoses, which 
includes Sweet’s syndrome, pyoderma gangrenosum, Behçet’s dis-
ease, rheumatoid neutrophilic dermatosis, familial Mediterranean 
fever and neutrophilic eccrine hidradenitis [60].
As described by Ely et al., these skin manifestations reproduce 
the progression through different cutaneous histologic patterns 
[35]. Indeed, the microscopic appearance of skin biopsy specimens 
changes with disease progression stage: the early manifestation is 
congestion of dermal venules with neutrophils and a peri vascular 
mononuclear cell infiltrate; the macular stage produces a peri-
vascular mononuclear cell infiltrate too; the papular stage pro-
duces edema of the papillary and reticular dermis. Neutrophil 
infiltration also shows a different location related to disease stage; 
in the early stage they are concentrated around dermal venules, 
but they are widely present in the dermis in the later stage. In 
older papules and vesicles, the neutrophilic infiltrate increases, 
incorporating nuclear debris and few eosinophils. Vesicle for-
mation is secondary to massive edema of the papillary dermis, 
while pustule formation is secondary to expulsion of neutrophilic 
debris through the epidermis. Although vascular dilatation and 
accumulation of neutrophils may be seen, there is no endothelial 
necrosis, infarction or fibrinoid degeneration [58–60].
Joints
Joint manifestations are highly variable in terms of onset time, 
duration, severity and distribution [61]. Arthritis is more com-
mon in females and no correlation between the amount of weight 
lost and the incidence of arthritis was observed. In most cases, 
arthritis occurs within the first 3 years following IBS. It is usually 
episodic, migratory and polyarticular, with peripheral joints more 
commonly affected than axial joints [61,62].
Knees, ankles, shoulders, wrists and metacarpophalangeal 
joints represent the sites most affected while axial skeleton involve-
ment has been rarely described and tendonitis and myalgias have 
also been reported [62,63]. Articular symptoms are typically remit-
tent and intermittent, and episodes can last for days to weeks 
followed by spontaneous resolution. In some patients, symptoms 
may become persistent from a few days to several months, thus 
mimicking rheumatoid arthritis or ankylosing spondylitis [61–64].
Objective findings are often mild, but joint effusions, syno-
vial thickening and joint swelling are present in many patients. 
Synovial fluid has been reported to display both inflammatory and 
noninflammatory features and within the synovium, a chronic 
synovitis with prevalent lymphocytic infiltrate is the most com-
mon histological finding [61,65]. Radiographic joint changes are 
not significant and usually do not include erosions, even if chronic 
erosive polyarthritis has also been described [66].
Laboratory findings
Routine blood analysis is usually normal. However, it is possible 
to observe rheumatoid factor and antinuclear antibody positivity, 
J-globulin increase, complement reduction, circulating immune 
complexes and cryoglobulins. In most patients, HLA haplotypes 
are not consistent with an underlying rheumatic disorder and in 
patients who showed HLA*B27 had presented with spondylitic 
symptoms earlier [61,64].
Treatment
Treatment of patients with BADAS is largely empiric and the use 
of drugs is based on the results of case reports or small case series 
[61–66]. Although the treatment of BADAS consists of antibiotics 
such as tetracycline, metronidazole or clindamycin to overcome 
bacterial overgrowth, relief is generally only temporary. In this 
regard it may be useful to rotate antibiotics, in a dose of antibiot-
ics for 1 week each month, or prokinetic agents such as cisapride 
that help to clear the small intestine [63,67]. NSAIDs may alleviate 
arthralgias and daily prednisone can control articular symptoms.
Patients with BADAS may benefit from treatment with systemic 
corticosteroids, cyclosporine or other drugs affecting the func-
tion of neutrophils, such as colchicine, sulphones or sulfasalazine, 
similar to those patients with neutrophilic disorders [12]. A novel 
therapeutic option might be the use of antibodies against TNF, 
which affects the recruitment of neutrophils in the skin [12].
Bypass reversal is curative in the majority of patients partially 
responding to pharmacological therapy [63,68,69]. In patients with-
out bowel bypass, treatment of  the underlying GI  disease has 
contributed to remission [8].
Unusual rheumatic manifestations after bariatric 
surgery
Over the years, several cases of BADAS have been described in 
substantial numbers of patients after IBS but rheumatic manifesta-
tions other than this syndrome have also been reported. In 1971, 
Shagrin et al. reported that seven out of 31 patients (23%) treated 
with jejuno colostomy for obesity developed articular symptoms. 
Most of the articular manifestations were transient, lasting only 
2 months, but in two patients they were more severe and lasted 
over 24 months. In one patient, severe articular symptoms required 
reconstitution of her bowel to the normal anatomical sequence. 
Complete relief and resolution of symptoms were  immediately 
observed [62].
In 1979, Goldman et al. described two patients with JIB who 
subsequently developed leukocytoclastic vasculitis. The authors 
report two cases in which necrotizing vasculitis with tenosynovitis 
arthralgia/arthritis syndrome developed after IBS. Each of these 
patients had jejunoileostomies, and the excluded segment was 
placed in an ileal–colonic anastomosis [70].
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In 1979, Zapanta et al. described 13 patients with arthritis 
related to JIB. These patients had a symmetrical polyarthritis, and 
eight also had extra-articular connective tissue disease manifesta-
tions such as alopecia, pleurisy, Achilles tendinitis, carpal tunnel 
syndrome and erythema nodosum-like lesions. The incidence of 
antinuclear antibodies and rheumatoid factor positivity, the pres-
ence of immune complexes and antibodies to intestinal flora, and 
the numbers of circulating T and B lymphocytes were comparable 
to those of patients who did not develop arthritis following IBS [71].
In 1982, Fagan et al. reported three patients with systemic 
inflammatory complications following JIB surgery for morbid 
obesity. They experienced asymmetrical polyarthritis, teno-
synovitis, sterile skin pustules, mucous membrane ulceration 
and retinal vasculitis resembling Behçet’s syndrome. Antibiotic 
therapy failed, whereas dapsone produced a sustained remission. 
Bacterial overgrowth was not observed in all patients, suggesting 
that bacteria may be required to initiate, but not to perpetuate, 
 inflammatory complications [72].
In 1983, Delamere et al. reported that 38 out of 107 patients 
who underwent JIB developed episodic polyarthralgia and arthri-
tis affecting both large and small joints, with a similar incidence 
of preoperative joint symptoms in those who did and in those 
who did not consequently develop the postoperative arthropathy. 
Reversal of the intestinal bypass was always associated with an 
immediate, complete and permanent remission of symptoms [73].
In 1985, Clegg et al. studied 13 patients after JIB surgery. All 
patients developed circulating immune complexes containing IgG 
and IgA and seven patients developed arthritis. IgA complexes 
were shown to contain secretory component, a protein predomi-
nantly associated with intraluminal IgA, in  significantly higher 
levels in patients with arthritis [74].
In 1997, Caux et al. described the fifth reported case of pan-
niculitis associated with BBS. These five patients had tender nod-
ules, nodules with discharge of necrosis or erythema nodosum-like 
lesions. A biopsy specimen revealed septal and lobular panniculitis 
and a glucose hydrogen breath test was consistent with bacterial 
overgrowth. The authors postulated that these rheumatic manifesta-
tions might have the same immunologic mechanism of BBS [61,75,76].
In 2003, Cox and Palmer reported a case of BBS associated with 
ileoanal pouch anastomosis that required high-dose prednisolone 
to control disease [9]. Since mycophenolate mofetil was known to 
be useful in pyoderma gangrenosum [77], it was as an effective 
steroid-sparing agent for this patient [9].
In 2006, Kawakami et al. described a case of fulminant BADAS 
characterized by necrotizing fasciitis-like severe skin and systemic 
manifestations that required differential diagnosis with cellu-
lites and necrotizing fasciitis and was treated with high doses of 
 corticosteroids [78].
In 2007, Kevans et al. described a patient who developed hand, 
wrist, elbow, hip and foot arthritis and diarrhea 3 weeks after a 
partial gastrectomy and vagotomy (Roux-en-Y  gastrojejenostomy 
with jejunojejunostomy) for a chronic nonhealing prepyloric 
gastric ulcer. Six weeks after the surgery diarrhea, abdominal 
pain and arthritis had completely resolved without medical 
therapy [79].
Expert commentary
Immune-related complications after JIB are underestimated; 
indeed, only scarce literature reports regarding these conditions 
are available to date, and it limits the possibility of defining the 
real incidence of the disease spectrum. BADAS represents a model 
in which surgical procedures trigger immune disorders, revealing 
a more complex scenario than initially thought and identifying a 
link between the surgeon and clinician. Here we have highlighted 
several mechanisms suggested to explain the pathogenesis of 
immune-related complications after JIB, showing the complexity 
and the wide clinical spectrum of the disease presentation.
Despite the increasing burden of immune-related conditions 
after bariatric surgery, a commonly accepted algorithm for treat-
ing patients is currently lacking, mostly because the adequate 
management of these patients has not yet been identified. The 
treatment of BADAS consists of antibiotics, but generally relief is 
only temporary. Reversal of bypass may be curative in the major-
ity of patients, pointing out the role of the blind loop in disease 
pathogenesis. Patients with BADAS may benefit from treatment 
with systemic corticosteroids or other immunosuppressive agents, 
including monoclonal antibodies against TNF.
Until now, published literature has reported large cohorts of 
patients still treated with JIB in selected patients in which differ-
ent procedures are not available or, alternatively, on the basis of 
new suggested indications, such as patients affected by unrespon-
sive Type 2 diabetes [68,80]. Thus, it is still possible that patients 
could undergo these surgical procedures and consequently develop 
immune-related diseases. From a rheumatologic point of view, 
it could be useful to remember, in the differential diagnosis of 
chronic arthritis, the clinical pattern of BBS.
Despite the fact that some surgical procedures are no longer per-
formed, immune-related conditions may represent a mid- to long-
term complication. Therefore, patients who underwent bariatric 
surgery may be referred to a rheumatologist several years later. 
On this basis and according to the authors’ experience, in the last 
5 years more than 15 patients were admitted to our  rheumatologic 
clinic with immune-related symptoms. These patients underwent 
JIB or other bariatric procedures many years before the onset of 
any immune-related symptoms, and due to their clinical manifes-
tations and lack of any other symptoms or biomarkers suggestive 
of chronic arthritis different from BADAS, we finally diagnosed 
BADAS. In this setting, we recommend considering BADAS in 
the differential diagnosis, particularly in those patients surgically 
treated decades ago.
The fact that surgical procedures other than JIB are not associ-
ated with bacterial stasis and bacterial overgrowth suggests that 
other pathogenetic mechanisms might determine the develop-
ment of BADAS. Moreover, the low incidence of the disease 
after such procedures suggests that a favoring background such 
as genetic predisposition may be required to see the full disease.
Only a close interaction between the surgeon and clinician, 
and a careful evaluation of patients before and after surgical 
procedures, will allow a precise and accurate definition of these 
immune-related conditions and will help us to understand the 
underlying pathogenic mechanisms.
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Five-year view
Although bariatric surgery is constantly evolving in an attempt 
to prevent complications, BADAS is still observed. One possi-
ble explanation is that while metabolic complications are well 
characterized, BADAS pathogenesis has not yet been fully clari-
fied. Hence, it would be difficult to achieve primary prevention 
unless the underlying mechanism is elucidated. In this setting, 
several groups have raised different hypotheses to explain the 
aberrant immune response that occurs after bariatric surgery 
but conclusive results are lacking. For example, the intriguing 
hypothesis that recognizes the intestinal flora of the blind loop as 
the abnormal activator of the immune response may also clarify 
the link between systemic autoimmunity and infections. On the 
other hand, it is of note that the CS appears to be a key player 
in the induction and perpetuation of BADAS and BADAS-like 
syndromes.
However, although bariatric surgery could represent a trigger 
factor to develop rheumatic/autoimmune disorders in non-pre-
disposed subjects, it could also unmask an underlying subclinical 
process. In addition, the lack of validated preventive strategies as 
well as predictors of BADAS development points out the need for 
cooperation between surgeons and clinicians to perform an early 
diagnosis. In this context, it might be inappropriate to consider 
BADAS as a rheumatologic disease requiring only antirheumatic 
treatment. Since surgery is the trigger event for disease develop-
ment, a ‘window of opportunity’ to apply a prophylactic and sur-
veillance program aimed to avoid immune-related complications 
is already available.
Indeed, the wide application of bariatric surgery in subjects 
with lower BMI increases the target population for such proce-
dures and, consequently, for immune complication. Therefore, 
besides surgical, nutritional and metabolic follow-up, an immu-
nological follow-up should also be performed in treated patients, 
particularly those with a familial history of autoimmune disorders.
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Key issues
s  After jejunoileal bypass, and occasionally other bariatric bypass procedures, a large spectrum of complications have been described, 
with rheumatic manifestation in up to 20% of cases.
s  Although bowel bypass syndrome, also called blind loop syndrome, is a well-recognized complication of bariatric surgery, the same 
syndrome was recognized in patients who had not had intestinal bypass surgery, and the term ‘bowel-associated dermatosis–arthritis 
syndrome’ (BADAS) was coined.
s  The pathogenesis of BADAS is currently poorly understood and only few data concerning this issue have been published in the 
literature; the intestinal flora of the blind loop and bacterial translocation could be the abnormal activator of the immune response, 
with a link between systemic autoimmunity and infections.
s  Symptom onset is variable, ranging from 3 months to 5 years postoperatively, and this syndrome may be self-limiting or recurrent. 
Differences in symptoms have been explained by a complexity of pathogenetic mechanisms.
s  The treatment of BADAS consists of antibiotics, but generally relief is only temporary. Reversal of bypass may be curative in the majority 
of patients. Patients with BADAS might benefit from treatment with systemic corticosteroids or other immunosuppressive agents, 
including antibodies against TNF.
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